Immunology Investor Event

Dupixent: Asthma 12+ Prevalence Number of patients (thousands) 23,500 18,420 4,900 46,820 Treated 1,600 1,790 600 3,990 Biologics eligible 900 800 200 1,900 42,000 43,000 44,000 45,000 46,000 47,000 0 1,000 2,000 3,000 US Europe(1) Japan Source: Sanofi analysis ICS: Inhaled Corticosteroids; OCS: Oral Corticosteroids (1) Germany, France, Italy, Spain & United Kingdom (2) For Europe, severe with persistent use of ICS or OCS. (3) For EU, severe uncontrolled or OCS dependent Immunology Investor Event 6 Moderate to severe with persistent use of medium to high dose ICS or OCS use or biologic(2) Uncontrolled despite persistent use of medium to high dose ICS + ≥1 controller or OCS(3) sanofi

View entire presentation